Repligen Announces Completion Of Patient Treatment In Phase 3 Clinical Trial Of RG1068 In MRI Imaging Of The Pancreas
Links shared publicly online about this topic.
- 1,663total visits
Repligen Announces Completion Of Patient Treatment In Phase 3 Clinical Trial Of RG1068 In MRI Imaging Of The Pancreas
Repligen Corporation (Nasdaq: RGEN) reported that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the p
View full resource at medicalnewstoday.com
Tags: Imaging Tests, Magnetic Resonance Imaging, Phase 3 Clinical Trial, Clinical Trial
Most Recently Shared on October 20, 2009 at 11:46 am By:
Repligen Announces Completion Of Patient Treatment In Phase 3 Clinical Trial Of RG1068 In MRI Imaging Of The Pa.. http://bit.ly/LmOze
Advertisement
